BioAtla (BCAB) EBIT Margin (2020 - 2026)

BioAtla (BCAB) posted quarterly EBIT Margin of 462.75% for Q4 2025, down 351.66% quarter-over-quarter from 102.45% in Q3 2024.

BioAtla (BCAB) EBIT Margin (2020 - 2026) Analysis & Trends

BioAtla's EBIT Margin history runs 4 years deep, the most recent figure standing at 462.75% for Q4 2025.

In Q4 2025, EBIT Margin changed N/A year-over-year to 462.75%; the TTM figure through Dec 2025 stood at 456.19% (up 21602.0% YoY), while the FY2025 annual figure was 2965.25%, down 229304.0% from the prior year.
EBIT Margin for Q4 2025 stood at 462.75%, down from 102.45% in the prior quarter.
The five-year high for EBIT Margin was 102.45% in Q3 2024, with the low at 12184.0% in Q2 2021.
The 3-year median for EBIT Margin is 462.75% (2025), against an average of 4249.73%.
Peak annual rise in EBIT Margin reached 980505 bps in 2021, while the deepest fall reached 980505 bps in 2021.
BioAtla's EBIT Margin stood at 12184.0% in 2021, then soared by 99 bps to 102.45% in 2024, then tumbled by 352 bps to 462.75% in 2025.
Business Quant data shows BCAB's EBIT Margin at 462.75% in Q4 2025, 102.45% in Q3 2024, and 12184.0% in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.15%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	32.54%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	17.93%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-0.36%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	19.75%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-35.57%
10	BioAtla	5.28 Mn	5.28 Mn	-	3.49%

Download Data